To the full analysis
Buyback calculator for Benitec Biopharma
Benitec Biopharma stock: key metrics
BNTCBenitec Biopharma had an operating margin of 0% and a return on invested capital (ROIC) of −29.4% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | −224.2% | −346.9% | no data |
| 2008 | −850.0% | −1,037.6% | −965.5% |
| 2009 | −666.7% | −1,148.2% | −1,055.5% |
| 2010 | −915.1% | −1,716.5% | −3,069.9% |
| 2011 | −604.9% | −1,992.6% | −2,255.8% |
| 2012 | −259.7% | −1,325.9% | −1,271.0% |
| 2013 | 67.7% | −1,494.9% | −766.8% |
| 2014 | 96.3% | −1,414.9% | −718.2% |
| 2015 | 96.3% | −1,607.6% | −1,064.7% |
| 2016 | 70.0% | −7,204.2% | −5,340.1% |
| 2017 | 18.3% | −8,132.4% | −2,860.4% |
| 2018 | 89.7% | −198.4% | −280.1% |
| 2019 | 91.1% | 21.2% | 21.4% |
| 2020 | 290.7% | −8,537.1% | −8,529.9% |
| 2021 | −108.5% | −23,044.1% | −23,528.8% |
| 2022 | 87.7% | −24,457.5% | −24,942.5% |
| 2023 | 100.0% | −25,441.3% | −26,082.7% |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
| 2026 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | no data | −26.6% | no data |
| 2008 | −100.0% | −84.7% | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | 200.0% | no data | −100.0% |
| 2011 | −62.5% | −79.1% | −47.4% |
| 2012 | −100.0% | −82.5% | −100.0% |
| 2013 | −12.6% | −41.5% | −12.3% |
| 2014 | −30.5% | −68.7% | −28.6% |
| 2015 | −36.7% | −34.0% | −26.0% |
| 2016 | −98.1% | −67.8% | −69.5% |
| 2017 | −26.0% | −61.8% | −24.6% |
| 2018 | −89.5% | −33.8% | −57.5% |
| 2019 | 22.5% | 16.9% | 13.6% |
| 2020 | −80.8% | −36.7% | −70.5% |
| 2021 | −69.4% | −69.7% | −64.9% |
| 2022 | −100.0% | no data | −100.0% |
| 2023 | −100.0% | no data | −100.0% |
| 2024 | −46.0% | −74.4% | −41.7% |
| 2025 | −39.0% | −45.5% | −38.1% |
| 2026 | −25.7% | −29.4% | −24.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Dec 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.